“The earlier cognitive impairment is detected the sooner and more efficiently the brain can be protected. The Altoida technology will be applicable in the direct care of patients and for research to help provide the next generation of therapeutic products. A test that will be easy to obtain, simple to perform, readily available, affordable, instantly diagnostic, reliable and can establish efficaciousness is a remarkable breakthrough in medicine”, Charles Neblett, M.D., Neurosurgeon – Baylor College of Medicine and Consultant/Medical Director at McNair Medical Institute, Houston TX